Comparative Pharmacology
Head-to-head clinical analysis: IBUPROFEN versus LODINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBUPROFEN versus LODINE.
Ibuprofen vs LODINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to anti-inflammatory, analgesic, and antipyretic effects.
Inhibition of prostaglandin synthesis via cyclooxygenase (COX) inhibition, with selectivity for COX-2 over COX-1.
200-800 mg orally every 6-8 hours; maximum 3200 mg/day.
200 to 400 mg orally every 6 to 8 hours as needed; maximum daily dose 1200 mg.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours; no accumulation with repeated dosing in normal renal function.
Clinical Note
moderateIbuprofen + Gatifloxacin
"Ibuprofen may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateIbuprofen + Rosoxacin
"Ibuprofen may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateIbuprofen + Levofloxacin
"Ibuprofen may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateIbuprofen + Trovafloxacin
"Ibuprofen may increase the neuroexcitatory activities of Trovafloxacin."
Terminal elimination half-life approximately 7.5 hours; in elderly or renal impairment, half-life may be prolonged up to 10 hours, requiring dose adjustment
Renal excretion of conjugated metabolites (about 90% as glucuronide and sulfate conjugates, <10% as unchanged drug); minor biliary/fecal elimination (<5%).
Primarily renal (60% as metabolites, <1% unchanged); biliary/fecal (30-35%)
Category D/X
Category C
NSAID
NSAID